Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
复制标题
DOI：
10.1002/jmri.25831
复制
发表时间：
2018-04
期刊：
影响因子：
--
通讯作者：
Awad IA
中科院分区：
文献类型：
--
作者：
Zeineddine HA;Girard R;Cao Y;Hobson N;Fam MD;Stadnik A;Tan H;Shen J;Chaudagar K;Shenkar R;Thompson RE;McBee N;Hanley D;Carroll T;Christoforidis GA;Awad IA
Quantitative Susceptibility Mapping (QSM) MRI allows accurate assessment of iron content in cerebral cavernous malformations (CCM), and a threshold increase by ≥6% in QSM has been shown to reflect new symptomatic hemorrhage (SH) in previously stable lesions. It is unclear how lesional QSM evolves in CCMs after recent SH, and whether this could serve as a monitoring biomarker in clinical trials aimed at preventing rebleeding in these lesions. This is a prospective observational cohort study. 16 CCM patients who experienced a SH within the past year, whose lesion was not resected or irradiated. The data acquisition was performed using QSM sequence implemented on a 3T MRI system. The lesional QSM assessments at baseline and yearly during 22 patient-years of follow-up were performed by a trained research staff including imaging scientists. Biomarker changes were assessed in relation to clinical events. Clinical trial modeling was performed using two-tailed tests of time-averaged difference (assuming within-patient correlation of 0.8, power = 0.9 and alpha = 0.1) to detect 20%, 30% or 50% effects of intervention on clinical and biomarkers event rates during two years of follow-up. The change in mean lesional QSM of index hemorrhagic lesions was +7.93% per patient-year in the whole cohort. There were 5 cases (31%) of recurrent SH or lesional growth, and twice as many instances (62%) with a threshold (≥6%) increase in QSM. There were no instances of SH hemorrhage or lesional growth without an associated threshold increase in QSM during the same epoch. We report novel biomarker changes which are sensitive to and twice as common as recurrent SH or lesional growth during follow-up of CCMs after recent bleed. The frequency of threshold QSM increase, or mean lesional QSM change per epoch may serve as monitoring biomarkers of CCM hemorrhage, reducing sample size requirements for proof of effect of novel therapies and enhancing the efficiency of clinical trials.
登录
查看更多内容
影响因子：
6.7
作者：
Tan H;Liu T;Wu Y;Thacker J;Shenkar R;Mikati AG;Shi C;Dykstra C;Wang Y;Prasad PV;Edelman RR;Awad IA
通讯作者：
Awad IA
影响因子：
6.7
作者：
Fritzsch, Dominik;Reiss-Zimmermann, Martin;Schaefer, Andreas
通讯作者：
Schaefer, Andreas
影响因子：
64.8
作者：
Landis, Story C.;Amara, Susan G.;Asadullah, Khusru;Austin, Chris P.;Blumenstein, Robi;Bradley, Eileen W.;Crystal, Ronald G.;Darnell, Robert B.;Ferrante, Robert J.;Fillit, Howard;Finkelstein, Robert;Fisher, Marc;Gendelman, Howard E.;Golub, Robert M.;Goudreau, John L.;Gross, Robert A.;Gubitz, Amelie K.;Hesterlee, Sharon E.;Howells, David W.;Huguenard, John;Kelner, Katrina;Koroshetz, Walter;Krainc, Dimitri;Lazic, Stanley E.;Levine, Michael S.;Macleod, Malcolm R.;McCall, John M.;Moxley, Richard T., III;Narasimhan, Kalyani;Noble, Linda J.;Perrin, Steve;Porter, John D.;Steward, Oswald;Unger, Ellis;Utz, Ursula;Silberberg, Shai D.
通讯作者：
Silberberg, Shai D.
影响因子：
8.3
作者：
Mikati AG;Tan H;Shenkar R;Li L;Zhang L;Guo X;Larsson HB;Shi C;Liu T;Wang Y;Shah A;Edelman RR;Christoforidis G;Awad I
通讯作者：
Awad I
影响因子：
19.7
作者：
Chen, Weiwei;Zhu, Wenzhen;Wang, Yi
通讯作者：
Wang, Yi